Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed supratentorial pure or mixed anaplastic oligodendroglioma~  * Unifocal or multifocal disease~ * Prior suspected or proven low-grade glioma eligible provided biopsy reveals pure or mixed anaplastic oligodendroglioma that has not been previously treated with radiotherapy and/or chemotherapy~* No equivocal oligodendroglial element~* No tumors predominantly located in the posterior fossa (i.e., brainstem or cerebellum)~* No spinal cord tumors~* No evidence of spinal drop metastasis or spread to noncontiguous meninges~PATIENT CHARACTERISTICS:~Age:~* 18 to 65~Performance status:~* Zubrod 0-1~Life expectancy:~* More than 12 weeks~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic:~* Bilirubin no greater than 2 times normal~* Aspartate aminotransferase (AST) no greater than 3 times normal~* Alkaline phosphatase no greater than 2 times normal~Renal:~* Creatinine no greater than 1.5 times normal~Other:~* No active infection~* No other medical problems that would preclude study participation~* No other malignancy within the past 3 years except carcinoma in situ of the cervix or nonmelanoma skin cancer~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* No prior chemotherapy for this malignancy~* No prior temozolomide~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy to the brain, head, or neck~Surgery:~* At least 14 days since prior surgery requiring general anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pre-RT temozolomide, RT plus temozolomide (Type: EXPERIMENTAL): Pre-radiation therapy (RT) temozolomide, RT plus temozolomide

Based on this trial design, predict the completion outcome and termination type (if applicable).